Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ME2 | P23368 | 2/20 | 0.47 |
| ▸ | ME1 | P48163 | 2/20 | 0.47 |
| ▸ | ME3 | Q16798 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27723056 | 0.89 | PANK3 (0.59) | PANK3MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1630859 | 0.87 | L3MBTL1 (0.58) | PANK3MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14269363 | 0.86 | PANK3 (0.56) | PANK3MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL21424864 | 0.84 | GRIN2D (0.59) | PANK3MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13115595 | 0.84 | KDM4E (0.67) | MEN1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL23601689 | 0.83 | SMO (0.57) | PANK3MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23600942 | 0.83 | CKS1B (0.54) | PANK3MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23972267 | 0.83 | PANK3 (0.60) | PANK3MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL23600946 | 0.83 | HRH3 (0.58) | PANK3MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL16371973 | 0.83 | PANK3 (0.44) | PANK3MEN1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701946-B1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | claimed |
| CN-1798735-A | 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase | NOVO NORDISK AS (DK) | 2006-07-05 | — | — | CN | claimed |
| EP-2479165-B1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-8802679-B2 | Glycine compound | ASTELLAS PHARMA INC. (JP) | 2014-08-12 | — | — | US | disclosed |
| EP-2479165-A1 | GLYCINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-07-25 | — | — | EP | disclosed |
| US-20120184520-A1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| CN-1798735-A | 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase | NOVO NORDISK AS (DK) | 2006-07-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184520-A1 | GLYCINE COMPOUND | SLC5A1, AQP1, VAPB | PANK3 2976/4885MEN1 2825/4885CYP1A2 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.